Aditxt (ADTX) Stock Price

Aditxt Price

NASDAQ·CLOSED
0.00
​
Market closed

Revenue at Aditxt has contracted by 58.2% per year over the past 4 years to 3,195.00 USD. For Aditxt, the net margin of -1,305,608.8% is down versus -44,148.6% a few years ago.

Aditxt stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt business model & stock analysis

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The company is headquartered in Mountain View, California and currently employs 2 full-time employees. The company went IPO on 2020-06-19. The firm is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The firm is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The firm is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.

Frequently asked questions about Aditxt

8 analysts currently rate the Aditxt stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Aditxt to generate revenue of 580.22 M USD and earnings per share of -2.75 USD.

Converted at the current exchange rate, the Aditxt share trades at 0.00 EUR (0.00 USD).

The Aditxt share (ADTX) is listed on 1 stock exchanges, including: NASDAQ (ADTX).

The expected revenue of Aditxt is 580.22 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Aditxt is -475.53 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Aditxt is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Aditxt stock.

The price-to-sales ratio (P/S) of Aditxt is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Aditxt stock.

The Eulerpool Quality Score for Aditxt is 2/10.

The ISIN of Aditxt is US0070258852. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Aditxt is A2PYWF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Aditxt is ADTX. The ticker symbol is used to trade Aditxt shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
122.88 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website aditxt.com
Currency
USD
Initial public offering
Jun 19, 2020
ISIN
US0070258852
Cusip
007025109
Sedol
BKVL9Z9
Market capitalization
0.10 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.00
P/S
P/Se
0.00
EV/EBIT
0.01
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-504.20 %
Last updated Oct 20, 2026, 12:42 PM

All fundamentals and in-depth analysis of Aditxt

Our stock analysis for Aditxt stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aditxt. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.